LMNL — Liminal BioSciences Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $27.62m
- $14.21m
- CA$0.40m
Annual cashflow statement for Liminal BioSciences, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -238 | -234 | -122 | -45.1 | -28.9 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 152 | 139 | 36.6 | -60.4 | -4.27 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 11.4 | -14.5 | 1.13 | 1.42 | -0.042 |
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -82.5 | -99.4 | -75.9 | -99.6 | -31.8 |
| Capital Expenditures | -5.13 | -4.44 | -2.05 | -0.463 | -0.019 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.731 | 40.5 | 4.35 | 171 | 3.84 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -5.86 | 36.1 | 2.31 | 171 | 3.82 |
| Financing Cash Flow Items | -4.9 | -12.2 | -6.94 | -5.18 | -1.61 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 72.2 | 118 | 57.4 | -8.42 | -45.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -15.8 | 53.9 | -16.2 | 63.4 | -71.3 |